Focal Laser Ablation of Prostate Cancer: Definition, Needs, and Future by Colin, Pierre et al.
Hindawi Publishing Corporation
Advances in Urology
Volume 2012, Article ID 589160, 10 pages
doi:10.1155/2012/589160
Review Article
Focal Laser Ablation of Prostate Cancer:
Deﬁnition,Needs,and Future
PierreColin,1,2 SergeMordon,1 PierreNevoux,1,2
Mohammed Feras Marqa,1 Adil Ouzzane,1,2 PhilippePuech,1,2 Gregory Bozzini,1,2
Bertrand Leroux,1 ArnauldVillers,1,2 andNacimBetrouni1
1Inserm U703, Universit´ e Lille Nord de France, CHRU Lille, 59037 Lille, France
2Department of Urology, CHRU Lille, Lille 59037, France
Correspondence should be addressed to Pierre Colin, pierre colin@msn.com
Received 13 January 2012; Revised 13 March 2012; Accepted 14 March 2012
Academic Editor: Eric Barret
Copyright © 2012 Pierre Colin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current challenges and innovations in prostate cancer management concern the development of focal therapies that allow the
treatment of only the cancer areas sparing the rest of the gland to minimize the potential morbidity. Among these techniques,
focal laser ablation (FLA) appears as a potential candidate to reach the goal of focusing energy delivery on the identiﬁed targets.
The aim of this study is to perform an up-to-date review of this new therapeutic modality. Relevant literature was identiﬁed using
MEDLINE database with no language restrictions (entries: focal therapy, laser interstitial thermotherapy, prostate cancer, FLA)
and by cross-referencing from previously identiﬁed studies. Precision, real-time monitoring, MRI compatibility, and low cost of
integrated system are principal advantages of FLA. Feasibility and safety of this technique have been reported in phase I assays.
FLA might eventually prove to be a middle ground between active surveillance and radical treatment. In conclusion, FLA may have
found a role in the management of prostate cancer. However, further trials are required to demonstrate the oncologic eﬀectiveness
in the long term.
1.Introduction
Prostate cancer is the most frequent cancer among men
over 50 years old in industrialized countries. With PSA
screening, development of new prostate biopsies protocols,
and MRI, the accuracy of detection and localization has
increased. Also, today a growing number of small-volume
and low-grade cancer foci are diagnosed in young healthy
men. Standard treatments for prostate cancersuch as surgery
or radiation involve the whole gland, even if the tumor is
localized. Despite their oncologic eﬃciency, radical treat-
ment modalities are associated with signiﬁcant morbidity
(urinary and sexual dysfunction) and may be linked to
useless overtreatment, which aﬀects quality of life of patients
diagnosed with very low development of potential small
localized tumors.
Today, 94% of low-risk cancers are treated with radical
treatment. In 2009, the ERSPC study has proven the value of
screening[1].Againofsurvivalof27%amongscreenedmen
aged55to69wasdemonstrated,withanaveragefollow-upof
9yearsafterdiagnosis.Butthisgainofsurvivalwasassociated
with a high rate of overdiagnosis and overtreatment.
Active surveillance can be an alternative to radical treat
ment in this indication. However, this strategy induces
important psychological stress for patients, and it is often
diﬃcult for clinicians to propose this management option to
young men with long life expectancies.
Today, a new treatment concept is emerging and is ter
med focal therapy. The challenge of current focal therapy
techniques is to treat only localized tumors sparing the rest
of the prostate to minimize the potential morbidity.
To be eﬀective, focal therapy must be (1) guided by imag
ing (to deﬁne the exact location of cancer area), (2) able to
target only the desired area (dosimetric planning), and (3)
followed by surveillance of the untreated areas.
Diﬀerent energy sources are being developed for this
indication, and some are currently under clinical proto-
cols such as cryotherapy, high-intensity focus ultrasound
(HIFU), or vascular photodynamic therapy (VTP).2 Advances in Urology
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Figure 1: Principle of FLA. The diﬀusing laser ﬁber was introduced by transperineal way (schematic midline sagittal section of prostate,
bladder, urethra, and striated sphincter). BW: bladder wall; BN: bladder neck; U: urethra; SS: striated sphincter; RUM: rectourethral muscle;
RW: rectal wall; PZ: peripheric zone; C: capsule of prostate; DF: Denonvilliers’ fascia; VPM: vesicoprostatic muscle; PSVF: posterior seminal
vesicle fascia; PPF: posterior prostatic fascia.
Focal laser ablation (FLA) by interstitial thermotherapy
could be another modality for prostate cancer focal therapy.
This technique presents the following beneﬁts: an ease of
use, low cost, and less cumbersome workstation. This paper
describes the mechanisms, history, and components of FLA
with an account of current clinical experience for prostate
cancer. The principle of transperineal FLA is illustrated in
Figure 1.
Relevant literature was identiﬁed using MEDLINE
databasewithnolanguagerestrictions(entries:focaltherapy,
laser interstitial thermotherapy, prostate cancer, focal laser
ablation) and then by cross-referencing from previously
identiﬁed studies. Articles were selected by their relevance to
the topic. Current clinical trials concerning FLA were found
using the database clinical trials conducted in the USA and
around the world (http://www.clinicaltrial.gov/).
2. FLA MechanismsandComponents
2.1. FLA Mechanisms. FLA is deﬁned as the thermal destruc-
tion of tissue by laser. For prostate cancer, this denomination
is preferred to the other names such as photothermal
therapy, laser interstitial tumor therapy, and laser interstitial
photocoagulationbecauseitdescribesboththeintentionand
the treatment [8].
FLA action is based on a photothermal eﬀect. The
thermal action results from the absorption of radiant energy
by tissue receptive chromophores inducing heat energy
in a very short time (few seconds) [18]. This increased
temperature may cause irreversible damages and remotely
in vivo destruction. The thermal eﬀect depends on the
amount of heat energy delivered but also on the depth of
light distribution. Consequently, the deep tissue damage is
dependent on the wavelength of the laser in action. Due
to weak absorption by water or hemoglobin, wavelengths
between 590 and 1064nm are classically used to obtain a
deeper tissue penetration.
The extension of thermal tissue damage depends on both
temperatureandheatingduration. Cell viability is inrelation
with thermostability of several critical proteins. Irreversible
protein denaturation may occur around 60◦C[ 19]. While
over 60◦C, coagulation is quasi-instantaneous, between 42
and 60◦C, a thermal damage is obtained with longer heating
periods.Theareasubmittedtosupraphysiologicalhyperther-
mia less than 60◦C will develop coagulative necrosis in 24
to 72h after treatment [6, 20]. Macroscopic appearance of
coagulation areas of FLA corresponds to well-demarcated
foci of necrosis surrounded by a small rim of hemorrhage
with no viable glandular tissue (benign or malignant) after
vital staining, based on immunoreactivity with cytokeratin
[9, 21].
2.2. FLA Material
2.2.1. Computed Dosimetric Planning. Pretreatment dosi-
metric planning of FLA requires three steps to predict the
extent of the coagulated necrosis [18]. An optothermal
model of FLA consists in calculating light distribution,Advances in Urology 3
temperature rise, and the extent of thermal damage. Light
distribution could be obtained using the Monte Carlo
simulation to estimate photons distribution in irradiated
tissue. This process is based on tissue optical properties at
the used laser wavelength.
Absorption of light in tissue causes a local elevation
in temperature. Tissue heat transfer due to the energy of
light deposited is described by the bioheat transfer equation
(Pennes’ equation).
Thermal damage in cells and tissue can be described
mathematically by a ﬁrst-order thermochemical rate equa-
tion, in which temperature history determines damage.
Damage is considered to be a unimolecular process, where
native molecules are transformed into a denatured/coagulat-
ed state through an activated state leading to cell death. It is
calculated from the Arrhenius law [22].
Previous theoretical models of prostate treatment have
generally assumed threshold damage temperatures of 50◦C.
These values are based on studies involving exposure dura-
tions of about seconds or greater. For instance, histological
evaluation performed by Peters et al. showed that the
thermal-injury boundary can be predicted from a threshold-
maximum temperature of approximately 51 degrees ◦C[ 3,
20, 23].
2.2.2. Laser Sources. As it was reported above, wavelengths
in the range of 590 to 1064nm are the most adequate to
induce a maximal photothermal eﬀect in human tissue. At
the beginning of interstitial laser coagulation development,
Nd:YAG laser (1064nm) was used. This laser source allowed
deep penetration into the tissue (10mm); however, this kind
of material is cumbersome due to the need for cooling
systems.
In 1998, with the development of laser for benign
prostate hypertrophy (BPH) treatment, small diode lasers
appeared allowing interstitial laser coagulation at 830nm
with transurethral application of diﬀusing ﬁbers [24, 25].
Thereafter, these diode lasers were used for hepatic and brain
tumors treatment in near-infrared (800–980nm) [26]. With
these wavelengths, while tissue penetration is weaker (5mm)
in comparison with Nd:YAG laser, these diodes present an
excellent energy eﬃciency permitting the minimization of
their cooling system. Improvements in the design of high-
power diode laser sources have made medical laser systems
smaller, more portable, more powerful, and less expensive
than previous generations. Since 2011, diode laser emitting
at 1064nm ± 10nm has been proposed and could replace
the Nd:YAG laser.
2.2.3. Optical Fibers. Light is delivered via ﬂexible quartz
ﬁbers of diameter from 300 to 600µm. Conventional bare-
tip ﬁbers provide a spherical lesion of about 15mm diameter
at their ends, but have been largely replaced by interstitial
ﬁbers consisting of cylindrical diﬀusing tips of 10 to 40mm
of length. These needles provide larger ablative area of up to
50mm [27, 28].
2.2.4. Temperature Monitoring
Two DiﬀerentTemperatureMonitoringSet-UpsAreProposed.
(i) Thermocouples placed at the laser probe are used to
control the laser power in the adaptive monitoring mode.
Usually,theinitiallaserpowerissetat15Wforeachﬁberand
the control temperature is set at 100◦C. As the temperature
measured by the laser ﬁber probe quickly increases to 100◦C,
the power delivered by the laser quickly decreases and
stabilizes at about 2W [11].
(ii) Fluoroptic temperature probes used to control the
temperature of speciﬁc structures. Due to their technology
theses probes (Model 3100, Luxtron Corp., Santa Clara,
California) are insensitive to the magnetic ﬁelds. These
probes can be used to validate the measurements performed
by MR thermometry. Usually, they are placed at the expected
ablation boundary to ensure that therapeutic temperatures
(55◦C or greater) are reached at the target borders and to
control that near-critical structures remain unaﬀected by
heat (by maintaining temperatures less than 42◦C) [29].
2.2.5. Real-Time MRI Control. Multiparametric MRI devices
are valuable tools for laser ﬁber guidance and control of
coagulative necrosis after FLA [3, 11]. As previously demon-
stratedforotherorgans,theextentoftissuenecrosisisvisible
in MRI (T1 weighted spin echo and FLASH sequences) [29,
30]. During the procedure, real-time 3D temperature maps
could be obtained using the proton resonance frequency
(PRF) shift. For MRI thermometry, a gradient-recalled echo
pulse sequence is rapidly repeated during FLA procedure.
With dedicated software, the acquired MR images are
analyzed in real time to estimate the thermal changes;
computation of the ablation zone maps was done using the
Arrhenius model of thermal tissue ablation.
3. ExperimentalTrials
3.1. Primary Development. The use of lasers to coagulate
tumorswasﬁrstproposedin1983byBown[31].Application
for prostate ablation started in 1993-94 [2, 12].
With development of laser treatment for BPH, feasibility
of FLA was established in canine model with a Nd:YAG laser
(1064nm) [2]. Johnson et al. reported an immediate well-
demarcated area of acute coagulative necrosis surrounding
each laser ﬁber pathway. A continuous and progressive enzy-
matic tissue liquefaction led within days to the development
of central necrotic cavities.
Amin et al. reported the ﬁrst clinical application of
FLA for local recurrence of prostate cancer after external
radiotherapy [12]. The procedure was performed under
intravenous sedation with 805nm diode laser. Laser ﬁbers
were inserted transperineally using 18G needles under US-
guidance and CT-scan control. A bladder and urethral
cooling was performed using continuous saline solution
perfusion with triple-lumen urinary catheter. Procedure was
well tolerated by patient with hospital discharge 24h after
treatment. A nonenhancing zone corresponding at ILC area
was visible in CT-scanning control at 10 days. Control4 Advances in Urology
biopsies at 3 months conﬁrmed presence of coagulative
necrosis in treated area and revealed cancer cells in other
untreated area. A second laser treatment was performed
without major side eﬀect [2, 12]. At that time, development
was limited by accuracy to localize the cancer areas on pre-
operative evaluation, computer dosimetric planning, and
imagery follow-up.
3.2. Preclinical Developments. Table 1 summarizes the diﬀer-
ent preclinical publications dealing with FLA.
In 2000, Peters et al. described MRI-guidance and real-
time thermometry for FLA in an in vivo canine prostate
model [3]. They used an 830nm diode laser (Indigo, Ethicon
EndoSurg) with a quartz-clad diﬀuser at the end of laser
ﬁber. Developments in MR imaging allowed accurate ﬁber
positioning and obtaining quantitative 3D maps of in vivo
temperature during the photothermal treatment. Animals
were sacriﬁced at 4 and 24h after the procedure. On
histologic sectioning, the necrotic area was surrounded by
hemorrhage and acute inﬂammation. In light microscopy,
intact viable cells were described in the necrotic area of
animal sacriﬁced after 4h.
As previously described, these tissue areas exposed to
supraphysiological hyperthermia (between 42 and 60◦C)
take from 24 to 72 hours for the full extent of lethal thermal
damage to be revealed by necrosis. The cells appeared
intact at this 4hr time point because their intrinsic lytic
enzymes have been thermally denatured and will likely
persist until new blood vessels bring inﬂammatory cells
to invade and digest the necrotic tissue. Consequently, on
posttreatment dynamic MRI control, the visible margins of
thermal necrosis were smaller than the histological ﬁnding.
The authors concluded that thermal damage planning using
MRI thermometry was needed.
In another study, after ex vivo calibration, Fuentes et al.
performed FLA at 980nm under MRI in canine prostate
model (2 animals) [4]. They realized 1.5 Tesla MRI real-
timethermometry,heatshockprotein(HSP)expression,and
cellular damage planning. The laser procedure consists in
h e a t i n ga t5W a t t sf o r9 0s e c o n d s .
The objective of obtaining a visible necrosis over 12mm
of diameter was reached on immediate histopathologic
examination. The authors concluded there was good corre-
lation between planning and histopathologic observations.
These ﬁndings were conﬁrmed by Staﬀord et al. working on
acanine model (5 dogs withhealthyprostateand 2 immuno-
suppressed dogs with prostate cancer) [5]. Diﬀerent levels of
energy were used at 980nm. This study demonstrated the
feasibility of MRI laser ﬁber guidance with template. The
laser ﬁber was placed in target site with accuracy (mean
standard deviation = 1.1mm ± 0.7). The correlation ratio
between planning and histopathologic ﬁndings was about
0.94.
More recently our research group prove reproducibility
of FLA in rat model with heterotopic tumor for one
energy level [6]. The volume of visible necrosis in MRI was
signiﬁcantly diﬀerent between 1 hour and 48 hours after FLA
procedure (P<0.001). This diﬀerence was explained by the
existence of a noncoagulated degenerative zone surrounding
the coagulative necrosis zone in the acute phase, which
developed coagulative necrosis after 48 hours as previously
described.Histologicalanalysisshowedacorrelationwiththe
mean necrosis volume obtained by MRI at 48h (r = 0.87).
Histopathologic ﬁndings were in accordance with cellular
damage planning.
In order to get a realistic model with materials presenting
optical properties values closer to those of human prostate,
Lindner et al. described a prostate phantom gel [10]. This
allows the implementation of the FLA under ultrasound,
CT, or MRI. The MR thermometry was validated with this
model by temperature measures correlation obtained by
ﬂuoroptic thermometry (Luxtron Model 3100 optical probes
were placed in situ in the phantom and could determine the
temperature in real time).
In another study, Woodrum et al. have tested FLA at
980nm on cadaveric model with MRI thermometry and
damage planning (Visualase system) [11]. They concluded
that MRI real-time thermometry and transperineal ﬁber
guidance thru a template is technically feasible.
4.ClinicalTrials
Table 2 summarizes the diﬀerent clinical publications on
FLA.
Several clinical studies in North America have recently
been reported [9, 13–15]. An initial phase I study
(NCT00448695, http://www.clinicaltrial.gov/) was published
by the team of Professors Trachtenberg and Haider in Tor-
onto who used a laser diode of 830nm already used for
the treatment of prostatic hyperplasia (Indigo Laser) [13].
After planning on MRI, the laser ﬁbers were placed by
a transperineal way; the monitoring of real-time process-
ing was achieved by contrast-enhanced ultrasonography
(CEUS). Necrotic lesions were visible on this examination
(hypovascular zone), and the volumes obtained were consis-
tent with those obtained on the control MRI.
Postoperative morbidity was negligible. Adverse events
reported most frequently consisted of a perineal discomfort
(25%) and mild hematuria (16%). Seventy-ﬁve percent
of patients treated could leave hospital the day after the
procedure. At 6 months, there was no signiﬁcant decrease in
erectile dysfunction score (IIEF-5) or worsening of urinary
symptoms assessed by the International Prostate Symptom
Score (IPSS).
On six-month biopsies, the authors reported short-term
oncological results with 67% of patients without recurrence
of tumor in the treated area [14]. These results described in
phaseItrialneedtobepondered:thegoalofthisstudywasto
assess the technical feasibility of FLA procedure. Also, short-
term oncologic results could be considered as interesting
but still limited by technical problems: in case of residual
cancer cells in the ablated zone (33% of patients), the failure
of treatment was explained either by poor overlap between
pretreatment planiﬁcation and posttreatment MRI results or
by extraprostatic tumour extension to which MRI did not
allude on pretreatment or posttreatment scan.Advances in Urology 5
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Thus, these limitations came from the poor visualization
of the tumor and the diﬃculty of ﬁber guidance to the target
previously deﬁned. These same limitations also apply for
other interstitial techniques (cryotherapy or photodynamic
therapy). Advances in MR imaging and those of ﬁber guid-
ance (nonrigid registration between MRI and ultrasound,
real time guidance under MRI, robotic) should resolve these
technical gaps.
Two other studies demonstrate the feasibility of focal
treatment of cancer by MRI-guided FLA system at 980nm
with Visualase system (NCT00805883 and NCT01094665)
[11, 28]. In the phase I trial NCT00805883 including 4
patients,thelaserﬁberguidancewasperformedaspreviously
reported [9]. A radical prostatectomy was performed one
week after the FLA procedure. Analysis of surgical specimens
concluded for good correlation between the volumes of
thermal damage visible on MRI and those actually recorded
on the vital stain histopathological parts set (Pearson’s
coeﬃcient R = 0.89). In the thermal ablation zone, lack of
viable tumor cells seen after immunostaining for cytokeratin
8 validates the scientiﬁc relevance of this minimally invasive
treatment modality [9, 21].
In phase I trial NCT01094665, Raz et al. described ﬁber
guidance under 3D MRI reconstruction by transperineal
approach in 2 patients. MRI thermometry and thermal
damage planning were calculated using Visualase system.
Transrectal CEUS was realized immediately after the FLA
procedure, and in case of residual vascularized target tissue,
another procedure with new ﬁbers position was performed.
The patients were discharged home within 3h, and no
adverse event or complication was noted at ≤1m o n t h
following treatment [15]. The same research team described
feasibility of robotic MRI-guided FLA in one case [16].
Recently, Woodrum et al. reported the case of one
patient with locally recurrent prostate cancer after radical
prostatectomy treated by FLA under 3T MRI guidance [17].
Authors reported no change in continence or potency after
the MRI-guided FLA procedure.
Today, three phase 1 trials are recruiting in Canada
(NCT01094665) and the USA (NCT01192438 and
NCT01377753), and many American centers are already
equipped with the Visualase system and have started to
publish on the FLA technique for focal treatment. In Europe,
a pilot study will open soon.
5. Discussion
Focal therapy for prostate cancer is recent and controversial
in the urological community.
Showing a high rate of overdiagnosis and overtreatment
concerning men with low-risk cancers, the results of interna-
tionalstudiesledtoincreasedinterestinalternativestrategies
and treatment options [1]. Also in selected patients, focal
therapy could be an interesting alternative between radical
treatment and active surveillance [32, 33]. Although the
idea of focal treatment is simple (ablating a speciﬁc and
previously deﬁned area sparing uninvolved tissue), the
application for prostate cancer met some diﬃculties: criteria
of patient’s selection for focal therapy, precise localization,
visualization and characterization of signiﬁcant cancer foci,
accuracy guidance of ablative energy in the area to be
treated,oncologiceﬃcacyevaluation,andﬁnallysurveillance
modalities.
Nowadays, we are witnessing the concomitant develop-
ment of the means of detection and the treatment modalities
of these small signiﬁcant cancers. Also, diﬀerent energy
sources are being tested for this indication. If limited
short-term oncologic results of prior focal trials concerning
cryotherapy or HIFU are encouraging, other ablative modal-
ities such as VTP or FLA have only demonstrated technical
feasibility to date [32].
FLA is an underdevelopment minimally invasive tech-
nique for in situ destruction of solid-organ tumors. Based on
the use of low-power laser, which delivers luminous energy
using an adapted optical system, FLA produces a coagulative
necrosis zone with a controlled volume, reducing the risk
of healthy adjacent structures damage (nerves, blood vessels,
sphincter) [6, 9, 13–15].
Before the generalization of this concept, many issues
have to be addressed. First, accurate localization of the
tumor is required. MRI technology is emerging as the
most important imaging tool for identifying low-volume
prostate cancers, characterizing tumours, helping in patient-
risk stratiﬁcation, and allowing targeted use of biopsy [33,
34]. Accuracy of MRI as just imaging modality was reported
inourpreviousworkwithradicalprostatectomyhistopathol-
ogy correlation in which MRI sensitivity and speciﬁcity for
identiﬁcation of signiﬁcant cancer foci (>0.5cc) were 86 and
94%, respectively [35]. Other teams also reported similar
results. Besides identiﬁcation, information concerning loca-
tion and contours of lesions is important to consider an
ablative technique. Important knowledge on modelling of
cancer morphology such as zone of origin and intraprostatic
patterns of spread of organ-conﬁned prostate cancers at
histopathology was made available for imaging interpreta-
tion and treatment planning decision [36, 37]. In a study
by Dickinson et al., when the location is depicted by biopsy
and the tumour is visualized by MRI, it accurately denotes
the speciﬁc location 83% of the time in the peripheral zone
for tumors larger than 4mm in diameter [38]. It should be
nevertheless noted that MRI application requires a degree
of discipline in its conduct, reporting, and evaluation to
obtain homogenous results among centers as emphasized by
a recent European consensus meeting [39]. If MR imaging
still lacks a strong validation, nowadays it remains the
most important available imaging tool for identifying early
prostate cancers and enabling focused use of energy ablative
modalities.
The second issue concerns the ability to place precisely
the laser-diﬀusing ﬁber within the target area. Using a
brachytherapy-stabilizing apparatus with modiﬁed template
grid and VariSeed system, Atri et al. were able to target
in transrectal ultrasonography a suspicious area visible in
MRI after rigid body registration [13]. Also, to compen-
sate prostate deformation using transrectal sonography, the
authors planned a target volume four times higher than the
MRIsuspiciousarea.InPhaseINCT00448695, Lindneretal.8 Advances in Urology
described the same transperineal technique using 3D US
and deformable registration for MR images fusion [14]. The
authors concluded that improved deformable registration
techniques might be able to minimize registration error and
improve targeting. The development of such commercial
devices with integrated laser is now achieved (e.g., Echolaser
by Esaote), but no data are available concerning FLA of
prostate application to the best of our knowledge.
Then, to enhance accuracy and facilitate real-time assess-
mentoflesionsize,thesameteamperformedﬁberplacement
manually under MRI procedure [15]. They used an MRI-
compatible template grid and multiplanar images to obtain
virtual 3D representation of the template with insertion
paths and ﬁber placement within the prostate. Accuracy
of MRI-template-based manual targeting was tested in a
preclinical study concluding to standard deviation of 1.1 ±
0.7mm in ﬁber placement [5]. Now emerges the possibility
of robotic guidance under MRI. In recent years, robotic MR-
guided biopsy of the prostate has been reported to be of
technical safety and a high degree of accuracy in the biopsy
needle placement [39, 40]. Lindner et al. described ﬁrst case
of robotic MRI-guided FLA [16]. Moreover the accuracy to
place the diﬀusing part of the laser ﬁber within the prostate
cancer can be improved: the authors demonstrated that the
robot can be used to produce oblique insertion angles to
provide adequate dose coverage of low-volume tumors or
with diﬃcult location (anterior). This placement technology
could be used for FLA under 3D-CEUS too but has not
been described with this energy source to the best of our
knowledge [41].
The third issue is the treatment planning required to
optimize therapy parameters to ensure the optimal coverage
of the area while sparing surrounding tissue. This issue is
challenging and still needs the development of dedicated
dosimetric tools as it was the case for radiotherapy and
brachytherapy. Recent key advances in MRI allowed us to
open some technological locks in FLA monitoring and guid-
ance. With computer modeling development for thermal
damage and multiplanar MR temperature imaging, it is
now possible to accurately determine the expected thermal
necrosis in region of interest and to control in real time
the photothermal eﬀect on homogeneous tissue [5, 7, 42].
Commercialisation of integrated system (laser source and
ﬁber, computerized planning, and monitoring solution) has
made MRI-guided FLA clinically relevant [14, 15]. However
some limits are still present. Principal variability observed
between predicted and obtained ablation areas is due to
tissue heterogeneity. This heterogeneity is in relation ﬁrstly
with own relaxation properties of the tissue (dependant
on zonal anatomy, presence of tumor, vascularization,
etc.) and secondly with changing of the tissular thermal
conductivity during temperature increasing. New nonlinear
calibrated computational model of the bioheat transfer
may provide a reasonable approximation of the laser-tissue
interaction, which could be useful for treatment planning in
heterogeneous areas such as prostate cancer [4, 7]. Another
limitation for thermal necrosis prediction is related with
cooled applicators. To avoid charring or photovaporization,
most teams are using cooled applicators to maintain a
temperaturebetween60and100◦Cduringtheheatingphase.
The use of these types of applicators necessitates computer
modeling of the rise in temperature of the in situ ﬂuid to
reduce systematic errors [4, 43].
In order to reduce morbidity for healthy adjacent
structures and reinforce speciﬁcity of FLA for cancer cells,
recent preclinical development have been described using
nanoparticles [44–46]. The goal of this technique is to pro-
duce photothermal coagulation in prostate tissue containing
nanoparticles by near-infrared (NIR) activation. Although
this is not shown speciﬁcally for prostate adenocarcinoma
cells, the preferential accumulation of nanoparticles in
cancer cells compared to healthy tissue has been suggested
(passive diﬀusion in tumour neovasculature by enhanced
permeability and retention eﬀect). Also, if this theoretically
selective accumulation was conﬁrmed, the NIR illumination
could activate a speciﬁc coagulation of the cancer cells. Thus,
photoactivation of nanoparticles may occur at power levels
that do not generate signiﬁcant damage to healthy tissue.
However the absence of toxicity of these nanoparticles must
ﬁrst be proven before considering an application in clinic.
In conclusion FLA is a potential tool for focal therapy
of low-risk prostate cancer. Precision, real-time monitoring,
MRI compatibility, and low cost of integrated system are
principal advantages of this minimal invasive therapy. Fea-
sibilty and safety of this technique have been reported in
phase I assays. Further trials are required to demonstrate the
oncologic eﬀectiveness in the long term.
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